Table 1. Neuroprotective effects of CDDO-MA on striatal dopamine and its metabolites in MPTP neurotoxicity.
| Animal (n) | Dopamine | DOPAC | HVA | |
| Acute MPTP model | ||||
| Control+PBS | 5 | 90.10±1.7 | 7.04±0.2 | 12.47±0.6 |
| CDDO-MA+PBS | 5 | 85.35±3.6 | 7.06±0.3 | 11.58±0.7 |
| Control+MPTP | 10 | 17.86±1.1## | 2.17±0.1## | 5.20±0.1## |
| CDDO-MA+MPTP | 10 | 46.22±6.3## ** | 4.28±0.4## ** | 8.26±0.5## ** |
| Chronic MPTP model | ||||
| Control+PBS | 5 | 87.73±2.6 | 8.00±0.2 | 9.78±0.4 |
| CDDO-MA+PBS | 5 | 86.99±3.5 | 7.88±0.3 | 9.20±0.3 |
| Control+MPTP | 13 | 41.60±4.6## | 1.57±0.1## | 4.05±0.2## |
| CDDO-MA+MPTP | 15 | 60.07±4.7# * | 2.32±0.3# * | 5.10±0.2# * |
a
Data are expressed as mean±SEM. Values represent as ng per mg protein.
b
#, p<0.05, ##, p<0.01compared to PBS groups; *, p<0.05, **, p<0.01 compared to control diet +MPTP group, ANOVA, Student-Newman-Keul's post test.